Skip to main content

Market Overview

UPDATE: ISI Group Upgrades Hologic as Shares Approach a Tipping Point

Share:

In a report published Tuesday, ISI Group analyst Vijay Kumar upgraded the rating on Hologic (NASDAQ: HOLX) from Buy to Strong Buy, and raised the price target from $25.00 to $25.50.

In the report, ISI Group noted, “Hologic's strategic decision to diversify its revenue base via acquisitions hasn't quite worked out, with poor capital returns and structural issues resulting in massive (~$5 Bn) capital destruction for long term shareholders. Shares have become increasingly volatile, with the Bears pointing to structural challenges in ThinPrep and Novasure, and reimbursement delays for 3D Tomo. The Bulls received a shot in the arm with the recent changes in management (new CEO, CFO off the Board, aligning management incentive to ROIC), against a backdrop of diagnostic share gains (highlighted by recent Quest Lab win) and upside from 3D Tomo in the longer term. We believe that HOLX is coming to a tipping point, with the Board looking to rectify a multi-year underperformance.”

Hologic closed on Monday at $20.10.

Latest Ratings for HOLX

DateFirmActionFromTo
Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

 

Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: ISI Group Vijay KumarAnalyst Color Upgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
ICADGuggenheimInitiates Coverage On24.0
SMBKRaymond JamesUpgrades27.0
WNSNeedhamMaintains88.0
EFXNeedhamMaintains260.0
GOOGLJefferiesMaintains2,700.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com